116
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Acute Pulmonary Actinomycosis Induced by Immunotherapy and Chemotherapy Used for SCLC Treatment: A Case Report and Literature Review

, ORCID Icon &
Pages 7575-7580 | Received 27 Aug 2023, Accepted 21 Nov 2023, Published online: 10 Dec 2023
 

Abstract

A 66-year-old male patient diagnosed with small-cell lung cancer received chemotherapy and immunotherapy, resulting in successful tumor control. However, the patient subsequently experienced a fever and rapid progression of the pulmonary cavity. Despite sampling bronchoscopic bronchoalveolar lavage fluid for targeted next-generation sequencing (tNGS), the cause remained unidentified. Adding bronchoalveolar lavage fluid to sense metagenomic next-generation sequencing (mNGS) confirmed the infection caused by actinomycetes. The patient’s condition improved after active anti-infection treatment. This case was further analyzed and discussed through a comprehensive literature review, focusing on molecular microbiological diagnosis and treatment processes. The points outlined were as follows: the advancement of molecular microbiology has gradually reduced the challenges associated with diagnosing rare infectious diseases such as pulmonary actinomycosis. Additionally, in immunodeficient individuals, certain infectious diseases with a chronic course may exhibit acute and aggressive characteristics, which is of concern to all colleagues. Currently, tNGS and mNGS are widely employed in clinical settings as practical tools for diagnosing infectious diseases. Notably, these two methods are not substitutes for each other but complement each other.

Ethics and Consent Statement

Written informed consent was obtained from the patient for the publication of this case report and any accompanying images, and our study was approved by the Ethics Committee at Affiliated Banan Hospital of Chongqing Medical University, to publish the case details.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

No public or private funding.